
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical cream containing azelaic acid, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing azelaic acid are listed in cream, gel and aerosol forms.
This dose form is water-containing (aqueous). Under USP <795>, aqueous preparations carry shorter default beyond-use dates than nonaqueous ones, and a preservative in the base allows a longer date than no preservative. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Azelaic acid is a naturally occurring dicarboxylic acid used as a topical dermatologic drug, manufactured as gel, foam and cream, and compounded in topical forms.
Azelaic acid is a dicarboxylic acid that occurs naturally in foods, in blood and in breast milk. As a skin medication it has several actions: it reversibly inhibits tyrosinase, an enzyme melanocytes use to make pigment; it kills acne-associated bacteria by disrupting their internal pH and an enzyme they rely on; it mildly slows keratinocyte overgrowth, which reduces comedone formation; and it reduces inflammatory signaling. The manufactured gel and foam (Finacea) are FDA-approved for the inflammatory papules and pustules of mild to moderate rosacea, and the manufactured cream (Azelex) is FDA-approved for acne. Prescribers may order azelaic acid compounded when they want a strength or base that is not manufactured, a preparation without a specific excipient such as propylene glycol, or a combination with another topical ingredient. Compounded azelaic acid is not FDA-approved and requires a prescription.
The manufactured gel carries no boxed warning. It is for skin use only, not for the eyes, mouth or vagina; the label reports iridocyclitis after accidental eye exposure. The gel is contraindicated in people allergic to propylene glycol or any other ingredient, and swelling of the face or throat, trouble breathing, hives or rash means stop and seek care. Isolated cases of skin lightening have been reported, and people with darker complexions should watch for early color changes. Tell your prescriber if you have asthma or recurring cold sores. Common side effects are burning, stinging, tingling, itching, dryness and redness where applied. The label lists no drug interactions. Use in pregnancy only if clearly needed. LactMed considers it low risk for a nursing infant but says not to apply it to the breast or nipple. If irritation persists, talk to your prescriber or pharmacist.
Azelaic acid is a naturally occurring dicarboxylic acid. Its labeled mechanism in rosacea is unknown; published reviews describe competitive, reversible tyrosinase inhibition with a preferential effect on hyperactive melanocytes, bactericidal activity against Propionibacterium acnes and staphylococci via membrane pH disruption and thioredoxin reductase inhibition, mild reversible reduction of keratinocyte proliferation and filaggrin synthesis, and anti-inflammatory and antioxidant effects through neutrophil ROS, NF-kB/MAPK, TLR2 and KLK5/LL-37 pathways. Percutaneous absorption of the gel could not be reliably determined; plasma levels after twice-daily use fell within the range produced by diet and endogenous metabolism, cutaneous metabolism is negligible, and excretion is mainly unchanged in urine with some beta-oxidation. Finacea gel and foam are labeled for inflammatory papules and pustules of mild to moderate rosacea; Azelex cream is labeled for acne. Published reviews describe azelaic acid use for melasma and post-inflammatory hyperpigmentation, which are not FDA-labeled indications. Prescribers may order compounded azelaic acid in a strength, base or combination that is not manufactured. Dosing frequency and concentration per prescriber. Monitoring per label: early signs of hypopigmentation in darker skin, local irritation, and exacerbation of asthma or herpes labialis. Not a controlled substance.
Wash your hands. Apply the amount on your label to clean, dry skin and rub it in gently. For a metered pump, each press delivers a set amount; your label states how many presses. For transdermal creams, apply to the area your label names and let it dry before dressing. Wash your hands afterward and avoid skin-to-skin contact with others at the application site until it has absorbed. Do not apply to broken skin unless told to.
Creams are aqueous. Under USP <795>, a preserved cream usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Follow the storage line on your label, keep from freezing, keep out of reach of children, and discard after the beyond-use date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)